All News Xlife Sciences AG BOERSE MUENCHEN

Equities

XLS

CH0461929603

Real-time BOERSE MUENCHEN Other stock markets 12:13:00 11/02/2022 am IST			5-day change	1st Jan Change
41.8 ^EUR	-0.48%		-.--%	-3.69%

23/04	Xlife Sciences Posts Higher FY23 Profit; Revenue Falls	MT
29/02	Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xlife Sciences : Praesentation	09/07	PU
Xlife Sciences AG: Successful General Assembly and New Trading Hours on the Sparks Segment of SIX	28/06	EQ
Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness	26/06	EQ
Xlife Sciences : Praesentation	03/06	PU
Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH and OCT Clinical GmbH	27/05	EQ
Xlife Sciences : Praesentation	07/05	PU
Xlife Sciences : Valuation Report 2023	30/04	PU
Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report	30/04	EQ
Xlife Sciences Posts Higher FY23 Profit; Revenue Falls	23/04	MT
Xlife Sciences AG Publishes 2023 Annual Report	23/04	EQ
Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland	03/04	EQ
Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Switzerland’s Xlife Sciences, Abu Dhabi Expand Existing Life Sciences Partnership	05/02	MT
Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Partners with Thermo Fisher Scientific and Masdar City	05/02	EQ
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline	29/12	EQ
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases	22/12	EQ
Xlife Sciences, Quant Team Up to Develop Biomarkers for Kidney Diseases Detection	20/12	MT
Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases	20/12	EQ
Revolutionary AI Algorithm «Prostate.Carcinoma.ai» Achieves EU MDR Class IIa Registration	18/12	EQ
Xlife Sciences to Sell Portfolio Company to 4D Lifetec	18/23/18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Xlife Sciences AG BOERSE MUENCHEN

Equities

XLS

CH0461929603

All News

Filters